MyChesCo on MSN10 小时
GSK’s AREXVY Vaccine Shows Promising Results Across Three RSV Seasons
GSK plc (LSE/NYSE: GSK) has released new data from the AReSVi-006 Phase III trial, demonstrating the efficacy and safety of ...
RSV疫苗的市场前景变了吗？
此外，近日GSK公布其RSV疫苗在预防60岁以上老年人3年（3个完整流行季）的保护效力，累积保护效力为63%，然而却呈现显著的下降趋势——从第1年的83%到第2年的56%再到第3年的48%，而Arexvy的初始效力在三款疫苗中已是佼佼者。
FiercePharma6 天
GSK touts 3-year data on RSV shot Arexvy after CDC's narrower usage recommendation
While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...
GSK Arexvy protects from RSV over three full seasons
GSK (NYSE:GSK) announced Tuesday that Arexvy, a Phase 3 trial for its FDA-approved vaccine against Respiratory Syncytial ...
GlaxoSmithKline股票前景因美国Arexvy销售不及预期而被修正 - 杰富瑞证券
周四，全球投资银行杰富瑞证券调整了GlaxoSmithKline (GSK:LN) (NYSE: GSK)的股票目标价，将其从之前的21.00英镑下调至20.00英镑。尽管如此，该公司仍维持对这家制药公司股票的"买入"评级。 此次修正是因为分析师预计GlaxoSmithKline第三季度的销售和利润可能低于市场预期，主要原因是美国Arexvy的表现不如预期。然而，分析师指出，该公司预计将重申其20 ...
GSK RSV shot 43% effective against severe disease in third year
GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...
The Pharma Letter5 天
GSK hopes for Arexvy boost after positive Phase III data
GSK shared new Phase III data on Arexvy, its RSV vaccine, at the 2024 CHEST annual meeting. Results show a single dose of ...
McKnight's Long-Term Care News6 天
RSV vaccine still 43.3 percent effective 3 years after people take it, trial shows
GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...
GSK Announces Positive Data From AReSVi-006 Phase III Trial For RSV Vaccine Arexvy
GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating ...
Seeking Alpha6 天
GSK Arexvy protects from RSV over three full seasons
GSK (NYSE:GSK) announced Tuesday that Arexvy, a Phase 3 trial for its FDA-approved vaccine against Respiratory Syncytial Virus (RSV), generated protection against the virus over three full seasons ...
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine ...
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV ...
GSK's Arexvy provides protection over three RSV seasons, trial shows
GSK has announced positive results from a phase III trial of its Arexvy RSV vaccine, showing that just one dose of the treatment could help protect older adults at risk of RSV disease over three ...